Mostrando 8 resultados de: 8
Filtros aplicados
Publisher
Drug Metabolism and Drug Interactions(2)
Pharmacogenomics(2)
Pharmacogenomics Journal(2)
Drug Metabolism and Personalized Therapy(1)
Molecular Psychiatry(1)
Área temáticas
Farmacología y terapéutica(7)
Medicina y salud(4)
Salud y seguridad personal(2)
Bioquímica(1)
Ginecología, obstetricia, pediatría, geriatría(1)
Origen
scopus(8)
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusAllele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers
ArticleAbstract: Aim: To determine allele and genotype frequencies of genes influencing anti-epileptic drug therapy iPalabras claves:ABCC2, anti-epileptics, CYP3A5, EPHX1, GABRA1, HNF4A, Mexican-Mestizo, NR1I2, pharmacogenetics, RALBP1, SCN1A, SCN2A, UGT1A1, UGT2B7Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusErratum: CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients (Molecular Psychiatry (2013) 18 (266))
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Alonso E., Dorado P., Jung H., López-López M., Naranjo M.E.G., Ortega A., Penãs-Lledó E.M., Trejo H.D.Fuentes:scopusEvaluation of drug-metabolizing enzyme hydroxylation phenotypes in Hispanic populations: The CEIBA cocktail
ReviewAbstract: Interindividual differences in response to drug treatments are mainly caused by differences in drugPalabras claves:Cocktail, Cytochrome P450 (CYP), Genotype, Hispanics, PhenotypeAutores:Adrián LLerena, Alonso-Vilatela E., Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes-Garro C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Enrique Terán, Estévez-Carrizo F.E., Ferreiro V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., Garza-Ocañas L., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde-Ramos B.P., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Naranjo M.E.G., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusInfluence of genetic variants and antiepileptic drug co-treatment on lamotrigine plasma concentration in Mexican Mestizo patients with epilepsy
ArticleAbstract: Genetic and nongenetic factors may contribute to lamotrigine (LTG) plasma concentration variabilityPalabras claves:Autores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopusInterethnic variability of pharmacogenetic biomarkers in Mexican healthy volunteers: A report from the RIBEF (Ibero-American Network of Pharmacogenetics and Pharmacogenomics)
ReviewAbstract: Mexico presents a complex population diversity integrated by Mexican indigenous (MI) (7% of Mexico'sPalabras claves:drug metabolizing enzymes, drug receptors, drug transporters, Mexicans, pharmacogeneticsAutores:Adrián LLerena, Fricke-Galindo I., Jung-Cook H., López-López M.Fuentes:scopusPharmacogenetics in Latin American populations: Regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders
Conference ObjectAbstract: Meeting report of the " Second Symposium on Pharmacology of Cytochrome P450 and Transporters " organPalabras claves:Cytochrome p450, Hispanics, Latin America, pharmacogeneticsAutores:Adrián LLerena, Alvárez M., Barrantes R., Borbón-Orejuela A., Calzadilla L.R., Céspedes C., Cobaleda J., de Andrés F., Delgado R., Dorado P., Doredo P., ElisaAlonso M., Enrique Terán, Estévez-Carrizo F.E., Ferrero V., Fiedler J., Francisco J.López Hernández, Galaviz-Hernandez C., García-Mesa M., Garza-Ocañas L., González-Naranjo M.E., González-Vacarezza N., Grazina M., Herrera L., Jiménez-Arce G., Lares-Asseff I., Lazalde B., Leonardo J. Beltrán, López-López M., Monroy-Jaramillo N., Moya G.E., Natalia Heras, Ochoa-Morales A., Ortega-Vázquez A., Ortiz-López R., Penãs-Lledó E.M., Pérez B., Pérez-Páramo Y.X., Ramírez-Roa R., Remírez D., Remírez-Figueredo D., Rodeiro I., Rojas-Martinez A., Rojas-Ponce R., Sarmiento-Sánchez A.P., Sosa-Macías M.G., Tarazona-Santos E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusRelevance of NR1I2 variants on carbamazepine therapy in Mexican Mestizos with epilepsy at a tertiary-care hospital
ArticleAbstract: Aim: We evaluated the potential influence of genetic (CYP3A5, EPHX1, NR1I2, HNF4A, ABCC2, RALBP1, SCPalabras claves:ABCC2, carbamazepine, EPHX1, Epilepsy, NR1I2, pharmacogeneticsAutores:Adrián LLerena, Dorado P., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M., Rojas-Tomé I.S.Fuentes:scopus